Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02887183 · ClinicalTrials.gov registry record · Phase 4
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 794
- Enrollment target
NCT02887183: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.
NCT02887183 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 794 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02887183, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 794 participants
- Enrollment target
Study Summary
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these biomarker changes with cardiac remodeling parameters, patient-reported outcomes and cardiovascular outcomes.
Primary Outcome
Change in concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline to one year
Interventions
- DRUG LCZ696 (sacubitril/valsartan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 794 participants |
| Start Date | 2016-10-25 |
| Est. Completion | 2018-10-22 |
| Phase | Phase 4 |
What the finished NCT02887183 record still lists
NCT02887183 is an interventional study that assigns participants to a tested intervention. The registered 794 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 1 intervention - of which LCZ696 (sacubitril/valsartan) is the first listed.
NCT02887183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02887183 about?
NCT02887183 is a clinical study titled "Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.". This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these biomarker changes with cardiac remodeling parameters, patient-reported outcome...
What is the current status of trial NCT02887183?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 794 participants. The study started on 2016-10-25. Estimated completion is 2018-10-22.
What interventions are being tested in trial NCT02887183?
The interventions under investigation include: LCZ696 (sacubitril/valsartan) (DRUG).
Who is sponsoring clinical trial NCT02887183?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02887183's enrollment target sits among peer trials
794 101st of 2000 higher than 1,900 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI